证券代码：600529 证券简称：山东药玻 公告编号：2024-067 山东省药用玻璃股份有限公司 关于使用闲置募集资金购买理财产品的进展公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●委托理财受托方:中国工商银行股份有限公司 ●委托理财金额：人民币 10,000.00 万元 ●委托理财产品名称：挂钩型结构性存款【专户型 2024 年第 416 期 I 款】 ●委托理财产品期限：96 天 ●履行的审议程序：公司于 2024 年 4 月 20 日召开了第十届董事 会第十二次会议和第十届监事会第十次会议，并于 2024 年 5 月 16 日 召开了 2023 年年度股东大会，审议通过了《关于使用闲置募集资金 购买理财产品的议案》，同意公司使用总额度不超过人民币 10 亿元的 暂时闲置募集资金进行购买安全性高、流动性好、期限不超过 12 个 月（含）的保本型理财产品（包括但不限于协定性存款、结构性存款、 定期存款、通知存款、大额存单等），并在上述额度内滚动使用，募 集资金理财使用额度及授权的有效期为自议案 ...

Group 1: Business Performance - In Q3 2024, all business segments remained stable except for the subsidiary Baotou Fenghui Packaging, which experienced a decline due to the milk industry impact [2] - The company anticipates an improvement in Q4 performance compared to Q3 based on current trends [2] - October sales performance exceeded the average level of Q3 [3] Group 2: Market and Pricing Impact - The impact of the 10th batch of national centralized procurement is uncertain as the official documents are pending release, but the current market and pricing remain stable [2] - The company is closely monitoring the capital market dynamics and aims to enhance its market image and brand value [4] Group 3: Product Development and Quality - The company expects stable growth in performance and borosilicate products in 2025 [3] - The good product yield rate for borosilicate glass bottles is currently around 70%, with a 5-10% gap compared to competitors like Schott and Corning [5] Group 4: Cost Management - In Q3, the price of soda ash dropped, while energy prices rose, resulting in overall stable costs [5] Group 5: Dividend Policy - The mid-term dividend was based on stable growth to reward investors, with policies outlined in the company’s articles [5] - The company has increased the dividend ratio for 2024 [6] Group 6: Management and Incentives - The incentive fund management method has been effective in maintaining stable growth, despite concerns about the low threshold for performance growth [3] - The management's income is comparable to other listed companies and may be higher than local averages [4]

山东药玻：10月销售情况优于Q3平均水平 预计2025年业绩稳定增长 财联社11月5日电，在今天上午举 行的2024年第三季度业绩说明会上，山东药玻总经理张军表示，公司Q3下滑业务有所改善，10月销售 情况优于Q3平均水平，预计Q4较Q3向好。 目前市场和价格稳定，2025年公司业绩和中硼硅产品预计继续保持稳定增长。 成本方面，主要原材料纯碱价格下降，但能源价格上升，当前总体成本保持稳定。 （财联社记者肖良华） ...

Investment Rating - The investment rating for Shandong Pharmaceutical Glass (600529) is "Buy" (maintained) [5] Core Views - The company reported a revenue of 3.83 billion yuan for the first three quarters of 2024, representing a year-over-year increase of 4.1%, and a net profit attributable to shareholders of 720 million yuan, up 17.3% year-over-year. However, Q3 2024 revenue was 1.24 billion yuan, down 1.0% year-over-year and down 6.0% quarter-over-quarter. The decline in Q3 is attributed to seasonal impacts and non-core business disruptions. The company maintains strong growth momentum and competitive advantages, with a focus on the pace of new round of centralized procurement [3][7]. Summary by Sections Financial Performance - For Q1-Q3 2024, the company achieved a gross margin of 32.1%, an increase of 3.9 percentage points year-over-year. The gross margin for Q3 2024 was 31.6%, up 0.9 percentage points year-over-year but down 2.5 percentage points quarter-over-quarter. The net profit margin for Q1-Q3 2024 was 18.8%, an increase of 2.1 percentage points year-over-year, with Q3 net profit margin at 19.8%, up 1.5 percentage points year-over-year and up 0.5 percentage points quarter-over-quarter [7][8]. Future Projections - The company expects revenues of 5.64 billion yuan, 6.50 billion yuan, and 7.59 billion yuan for 2024, 2025, and 2026 respectively, with year-over-year growth rates of 13%, 15%, and 17%. The net profit attributable to shareholders is projected to be 940 million yuan, 1.13 billion yuan, and 1.38 billion yuan for the same years, with growth rates of 22%, 20%, and 21% respectively. The earnings per share (EPS) are forecasted to be 1.42 yuan, 1.71 yuan, and 2.07 yuan for 2024, 2025, and 2026 respectively [7][8]. Market Position - The company is positioned as a leader in molded bottles, with stable growth in demand for pharmaceutical glass and continuous improvement in product structure. The expansion into new product categories and overseas markets has been effective, highlighting the importance of the company's growth momentum [3][7].

Investment Rating - The investment rating for the company is "Buy" and is maintained [2][7]. Core Views - The company reported a revenue of 3.825 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 4.12%, while the net profit attributable to the parent company was 720 million yuan, up 17.29% year-on-year [2]. - In Q3 2024, the company achieved a revenue of 1.239 billion yuan, a slight decline of 0.99% year-on-year, but the net profit for the same quarter was 245 million yuan, reflecting a year-on-year increase of 7.23% [2]. - The revenue growth has slowed down, but Q4 is expected to accelerate due to the gradual implementation of centralized procurement [2][3]. - The gross margin for Q3 2024 was 31.6%, showing a year-on-year increase of 0.9 percentage points but a decrease of 2.5 percentage points quarter-on-quarter, primarily due to product mix effects [2][3]. Financial Performance - The company forecasts revenues of 5.573 billion yuan and 6.196 billion yuan for 2024 and 2025, respectively, with year-on-year growth rates of 11.9% and 11.2% [4]. - The net profit attributable to the parent company is projected to be 948.31 million yuan in 2024 and 1.0965 billion yuan in 2025, with growth rates of 22.24% and 15.63% respectively [4]. - The earnings per share (EPS) are expected to be 1.43 yuan in 2024 and 1.65 yuan in 2025, with corresponding price-to-earnings (P/E) ratios of 17.89X and 15.48X [4][6].

Investment Rating - The report maintains a "Recommended" rating for the company [2][4]. Core Views - The company achieved a revenue of 3.825 billion yuan in Q1-Q3 2024, representing a year-on-year increase of 4.12%. The net profit attributable to shareholders was 720 million yuan, up 17.29% year-on-year [2]. - The report highlights the stable growth in Q3, with a revenue of 1.239 billion yuan, a slight decrease of 0.99% year-on-year, while the net profit increased by 7.23% to 245 million yuan [2]. - The report emphasizes the positive outlook for the company's growth driven by the increasing demand for borosilicate molded bottles, export market conditions, and the reduction in soda ash costs enhancing profit margins [2]. Financial Performance Summary - For Q1-Q3 2024, the gross margin was 31.58%, an increase of 0.88 percentage points year-on-year, while the net profit margin was 19.80%, up 1.52 percentage points year-on-year [2]. - The report notes a decrease in the average price of heavy soda ash to 2012 yuan/ton, down 18.2% year-on-year, while the price of LNG increased to 4906 yuan/ton, up 19.6% year-on-year [2]. - The company adjusted its net profit forecasts for 2024-2026 to 934 million, 1.085 billion, and 1.242 billion yuan, respectively, corresponding to PE ratios of 18, 16, and 14 times [2][5].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 32.54 CNY, reflecting a 21x PE for 2024 [4][6]. Core Views - The company achieved a net profit of 245 million CNY in Q3, marking a year-on-year increase of 7.23%. For the first three quarters, the revenue and net profit reached 382.5 million CNY and 72 million CNY, respectively, with year-on-year growth of 4.12% and 17.29% [1]. - The report highlights that the company's net profit margin continues to grow, reaching a historical high of 19.80% in Q3, up 1.52 percentage points year-on-year [2]. - The company is expected to maintain high growth due to increasing demand in the downstream market and favorable raw material prices, which are anticipated to enhance profitability further [4]. Financial Performance Summary - In Q3, the company reported a revenue of 1.239 billion CNY, a decrease of 0.99% year-on-year, while the net profit for the same period was 245 million CNY, an increase of 7.23% year-on-year [1]. - The overall gross margin for the first three quarters was 32.10%, up 3.89 percentage points year-on-year, with Q3 gross margin at 31.58% [2]. - The company's asset-liability ratio increased to 21.96%, up 3.73 percentage points year-on-year, while operating cash flow improved to 813 million CNY, an increase of 86 million CNY year-on-year [3]. Earnings Forecast - The company is projected to achieve net profits of 1.03 billion CNY, 1.27 billion CNY, and 1.50 billion CNY for 2024, 2025, and 2026, respectively, with growth rates of 32.54%, 23.12%, and 18.17% [5][10]. - The report anticipates a steady increase in revenue, forecasting 5.91 billion CNY in 2024, 6.82 billion CNY in 2025, and 7.75 billion CNY in 2026, with corresponding growth rates of 18.65%, 15.40%, and 13.58% [5][12].

山东药玻：前三季度净利润7.2亿元 同比增长17.29% 财联社10月28日电，山东药玻发布2024年第三季度 报告，公司前三季度实现营业收入38.25亿元，同比增长4.12%；净利润7.2亿元，同比增长17.29%；基 本每股收益1.0856元。 其中，第三季度实现净利润2.45亿元，同比增长7.23%。 查看公告原文 ...

Financial Performance - The company's operating revenue for Q3 2024 decreased by 0.99% year-on-year, totaling CNY 3,824,950,899.24[2] - Net profit attributable to shareholders increased by 7.23% year-on-year, reaching CNY 720,431,146.66[2] - The basic earnings per share for the period was CNY 1.0856, reflecting a year-on-year increase of 17.29%[2] - Total operating revenue for the first three quarters of 2024 reached CNY 3,824,950,899.24, an increase from CNY 3,673,747,350.74 in the same period of 2023, representing a growth of approximately 4.1%[16] - Net profit for the first three quarters of 2024 was CNY 720,431,146.66, compared to CNY 614,234,124.50 in 2023, reflecting a growth of approximately 17.3%[17] - The total comprehensive income for the third quarter of 2024 reached ¥720,431,146.66, an increase from ¥614,234,124.50 in the same period of 2023, representing a growth of approximately 17.3%[18] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 9,979,007,795.90, representing a 7.09% increase compared to the end of the previous year[3] - Total assets as of the end of Q3 2024 amounted to CNY 9,979,007,795.90, up from CNY 9,318,721,550.84 at the end of Q3 2023, showing an increase of approximately 7.1%[15] - Total liabilities increased to CNY 2,191,409,778.84 in 2024 from CNY 1,784,212,772.67 in 2023, representing a growth of about 22.8%[15] - The company's total non-current assets reached CNY 4,033,853,686.34, compared to CNY 3,773,115,590.79 in the previous year, indicating an increase of approximately 6.9%[15] - The total equity attributable to shareholders increased to CNY 7,787,598,017.06 in 2024 from CNY 7,534,508,778.17 in 2023, reflecting a growth of about 3.4%[15] Cash Flow - Cash flow from operating activities for the period was CNY 813,077,771.74, showing an increase of 11.78% year-on-year[2] - Cash inflow from operating activities for the first three quarters of 2024 was ¥3,999,117,010.56, up from ¥3,380,687,417.80 in 2023, indicating a growth of approximately 18.3%[19] - Net cash flow from operating activities for the first three quarters of 2024 was ¥813,077,771.74, compared to ¥727,382,605.46 in 2023, showing an increase of approximately 11.8%[21] - Cash inflow from investment activities was ¥4,781,146,372.42 in the first three quarters of 2024, compared to ¥3,776,990,140.61 in 2023, representing a growth of about 26.5%[21] - Net cash flow from investment activities for the first three quarters of 2024 was -¥914,709,385.13, worsening from -¥773,012,986.54 in 2023[21] Shareholder Information - The number of shareholders holding more than 5% of shares includes Shandong Luzhong Investment Co., Ltd. with 19.50% ownership[10] - The top ten shareholders collectively hold a significant portion of the company's shares, with Shandong Luzhong Investment Co., Ltd. holding 129,380,980 shares[10] - The company reported a total of 54,216,959 shares held by China Bank Co., Ltd. - Huabao CSI Medical ETF, representing 8.17% of total shares[10] - The company has engaged in securities lending activities, with 3,000,000 shares held in a credit securities account by Shandong Luzhong Investment Co., Ltd.[11] Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[12] - Research and development expenses increased to CNY 115,324,642.87 in 2024 from CNY 93,377,102.40 in 2023, marking a rise of about 23.5%[17] Other Financial Metrics - Non-recurring gains and losses for the period totaled CNY 11,422,297.56, with a cumulative amount of CNY 31,417,481.81 for the year-to-date[5] - The company reported a significant increase of 236.16% in asset disposal gains compared to the same period last year[7] - The company experienced a 40.10% increase in trading financial assets year-to-date, attributed to increased purchases of structured bank deposits[6] - The company’s other income increased by 146.92% year-on-year, primarily due to an increase in VAT deductions[7] - Total current assets as of September 30, 2024, amounted to CNY 5,945,154,109.56, an increase from CNY 5,545,605,960.05 as of December 31, 2023, representing a growth of approximately 7.2%[13] - Cash and cash equivalents decreased to CNY 1,087,938,009.78 from CNY 1,466,329,926.87, a decline of about 26%[13] - Inventory increased to CNY 1,206,411,867.83 from CNY 1,054,610,571.71, reflecting a growth of approximately 14.4%[13] - The company's fixed assets rose to CNY 3,473,295,662.24 from CNY 2,994,659,152.84, indicating an increase of around 16%[13] - The total receivables, including notes and accounts, reached CNY 1,770,484,575.04, up from CNY 1,646,346,464.57, marking an increase of about 7.6%[13] - The company's financial expenses showed a decrease, with a net financial cost of -CNY 25,023,212.79 in 2024 compared to -CNY 28,720,110.06 in 2023, indicating improved financial management[17] - Deferred income increased significantly to CNY 110,700,597.67 in 2024 from CNY 57,620,534.05 in 2023, representing an increase of approximately 91.9%[15] - Cash outflow from operating activities totaled ¥3,186,039,238.82 in the first three quarters of 2024, compared to ¥2,653,304,812.34 in 2023, marking an increase of about 20.0%[21] - Cash and cash equivalents at the end of the third quarter of 2024 stood at ¥929,434,878.59, slightly down from ¥934,200,506.87 at the end of the same period in 2023[21] - The company reported tax payments of ¥237,079,540.17 in the third quarter of 2024, compared to ¥204,970,310.22 in 2023, reflecting an increase of approximately 15.6%[21] - The company’s cash inflow from sales of goods and services for the first three quarters of 2024 was ¥3,872,882,678.24, up from ¥3,308,413,735.28 in 2023, indicating a growth of about 17.0%[19]

证券代码：600529 证券简称：山东药玻 编号：2024-065 山东省药用玻璃股份有限公司 第十届监事会第十二次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 第一部分、监事会会议召开情况 山东省药用玻璃股份有限公司（以下简称"公司"或"山东药玻"） 第十届监事会第十二次会议通知，于2024年10月15日以书面方式向全 体监事发出，会议于2024年10月26日上午在公司研发大楼六楼会议室 召开，应到监事3名，现场实到监事2名，1名监事通讯表决，会议由 公司监事会主席召集并主持，符合《公司法》和《公司章程》的有关 规定。 第二部分、监事会会议审议情况 本次会议由监事会主席主持，以记名投票方式审议通过了《公司 2024年第三季度报告》，具体内容详见在上海证券交易所网站 （www.sse.com.cn）披露的《山东省药用玻璃股份有限公司2024年第 三季度报告》。 虚假记载、误导性陈述或者重大遗漏。 第三部分、备查文件 1、山东省药用玻璃股份有限公司第十届监事会第十二次会议决 议。 特此公告。 山东省药用玻璃股 ...